Navigation Links
Clostridium difficile Infection: Strategic Approaches for Better Outcomes
Date:6/15/2009

Complimentary Continuing Education Live Lectures for Healthcare Professionals

VOORHEES, N.J., June 15 /PRNewswire/ -- In recent years, the epidemiology of Clostridium difficile infection (CDI) has been changing. This trend may be the result of antimicrobial use, infection control practices, or other factors. It is critical for healthcare professionals to be aware of the epidemiology of this virulent pathogen and apply evidence-based principles for diagnosis, treatment, and prevention.

To address the need for current education on CDI, Robert Michael Educational Institute LLC (RMEI) and Postgraduate Institute for Medicine (PIM) are jointly sponsoring complimentary continuing education lectures conveniently located at medical institutions across the United States. This activity is supported by an educational grant from ViroPharma Incorporated and is accredited for physicians, pharmacists, and registered nurses.

Faculty for these lectures are leading experts in infectious diseases, gastroenterology, microbiology, epidemiology, and infection control.

Healthcare professionals can visit www.RMEI.com/CDILectures, e-mail CDILectures@RMEI.com, or call toll-free to 1-866-992-9940 to schedule a lecture.

"Robert Michael Educational Institute LLC is committed to providing healthcare professionals with opportunities for quality, innovative, and convenient continuing medical education," says President and CEO, Robert M. Colleluori.

RMEI is a medical education company that specializes in independent, certified, and non-certified education. The goal of all certified RMEI educational offerings is to promote a spirit of lifelong learning and continuous professional development. RMEI works closely with medical experts to design activities that improve diagnosis and treatment leading to better outcomes for patients. These activities include national and international symposia, teleconferences, live meetings, enduring print materials, and interactive Internet programs.

For other educational opportunities, please visit www.RMEI.com.


'/>"/>
SOURCE Robert Michael Educational Institute LLC
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Medarex and Massachusetts Biologic Laboratories Announce Primary Objective Achieved in Phase 2 Trial of Monoclonal Antibody Combination for the Treatment of Clostridium difficile Associated Diarrhea (CDAD)
2. Clostridium difficile Infection: Current Challenges and Controversies
3. Germgards Ultra-Fast Hand Hygiene Solution Protects Against Deadly MRSA, C difficile, and Influenza Virus
4. Strategic Diagnostics to Present at Two Upcoming Investor Conferences
5. Strategic Diagnostics Updates Roth Conference Presentation Time
6. Heritage and Ipca Enter Into Strategic Alliance for Generic Pharmaceutical Products
7. NovaQuest Advances Virtual Development Model With Strategic Investment in TOPIGEN Pharmaceuticals
8. PDL BioPharma Announces Significant Strategic and Portfolio Changes to Focus on Antibody Discovery and Development
9. Genstar Names Michael Hurt to Its Strategic Advisory Board
10. Pharsight Expands Strategic Consulting Services Team
11. VaxGen Further Restructures to Preserve Cash as It Pursues Strategic Initiatives
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/12/2017)... ... January 12, 2017 , ... ... Vertebral Technologies, Inc., announces the successful outcome of the first lumbar fusion ... VTI (Vertebral Technologies, Inc.) has partnered with Mexico-based medical product company BioMedical ...
(Date:1/12/2017)... AURORA, Colo (PRWEB) , ... January 12, 2017 ... ... and then to targeted treatments, 26-year-old Lisa Rosendahl’s doctors gave her only a ... eLife describes a new drug combination that has stabilized Rosendahl’s disease and increased ...
(Date:1/12/2017)... The report "Direct-Fed Microbials Market by Type (Lactic Acid Bacteria and Bacillus), Livestock (Pork/Swine, Poultry, ... to 2022", published by MarketsandMarkets, the global market is estimated to be valued ... by 2022, at a CAGR of 6.96% from 2016. ... ... ...
(Date:1/11/2017)... ... January 11, 2017 , ... ... clinics in Peru studying the pathogens that cause malaria and tuberculosis. Seeing firsthand ... path of discovery. , Now, as an assistant professor of biology and biotechnology ...
Breaking Biology Technology:
(Date:12/15/2016)... , Dec. 15, 2016   WaferGen Bio-systems, ... held genomics technology company, announced today that on December ... Qualifications Department of The Nasdaq Stock Market LLC which ... bid price of WaferGen,s common stock had been at ... WaferGen has regained compliance with Listing Rule 5550(a)(2) of ...
(Date:12/15/2016)... Advancements in biometrics will radically ... wellbeing (HWW), and security of vehicles by ... vehicles begin to feature fingerprint recognition, iris ... monitoring, brain wave monitoring, stress detection, fatigue ... detection. These will be driven by built-in, ...
(Date:12/15/2016)... Dec. 14, 2016 "Increase in mobile transactions ... The mobile biometrics market is expected to grow from ... by 2022, at a CAGR of 29.3% between 2016 ... as the growing demand for smart devices, government initiatives, ... "Software component is expected to grow at a ...
Breaking Biology News(10 mins):